France: Recent Developments in Pharmaceutical and Bioethics Law

Last Updated: 16 December 2004
Article by Christian Belloin and Camille Ricaud


Law n° 2004-806 dated 9 August 2004 relating to health care policy implements the EU Clinical Trials Directive 2001/20/EC of 4 April 2001 on medicinal products for humans and reforms the French law n° 88-1138 "Huriet-Sérusclat" of 20 December 1988 on the protection of clinical trial subjects.

The amending law modifies the existing provisions of the French Public Heath Code in the following areas:

Protection of clinical trial subjects

Specific clinical trial subjects are now strictly protected including are minors and incapacitated adults who are either covered by a legal protection measure or unable to give their informed legal consent. They can only participate in clinical trials if clinical trials presenting the same level of efficiency cannot be carried out on other clinical subjects and subject to the following conditions:

(a) either the potential expected benefit for these clinical trial subjects justifies the risks incurred; or

(b) the potential expected benefit for other minors or individuals in the same situation justifies these clinical trials.

Prior authorisation process for clinical trials

In most cases, a favourable opinion of an ethics committee ("Comité de protection des personnes") and an approval of the competent national authority, "L'Agence française de sécurité sanitaire des produits de santé", are required for any clinical trial launched by any sponsor. Both approvals can be requested simultaneously.

The applicable decree setting the time period between the filing of the sponsor's requests and the responses from the Authorities has not been yet implemented. However, Directive 2001/20/CE has scheduled a maximum period of 60 days. The priority for the French Authorities, in order to remain competitive as compared to other EU countries, is to elect a short time period.

Sponsors' liability regime

The new law has amended the sponsors' liability regime. Under the previous legislation, the liability of the sponsor differed, depending on whether or not there was an individual direct benefit for the clinical trial subjects. The new law has deleted the wording which has made this distinction up until now, and replaced it with a "benefit/risk" evaluation.

This will have consequences for insurance coverage. The amendment of this provision took effect immediately upon enactment of the new law. Sponsors must therefore review their insurance coverage in this respect.

The French Authorities have not yet confirmed if a sole sponsor must be appointed to assume liability for a clinical trial set up throughout several EU countries. Under the new law companies outside the EU must appoint a legal representative to carry out clinical trials in any EU country. This new provision could lead to such legal representatives.

Investigational medicinal products

The definition of an investigational medicinal product provided by Directive 2001/20/CE has been inserted in the section of the French Health Code relating to medical products for human use (that is, Article L.5121-1-1).

The legal and regulatory provisions of the French Health Code require that imports of investigational medicinal products from countries outside the EU to be licenced by the head of the competent French Authority ("Agence française de sécurité sanitaire des produits de santé"). In order to obtain such a licence, the request for an authorisation to import such products must provide, inter alia, the names and addresses of the individual and the legal entity responsible for importing the investigational medicinal products. The legal entity in charge of importing the investigational medicinal products must be a pharmaceutical company ("établissement pharmaceutique") of which one of the managers must be a pharmacist. The pharmacist must certify that the investigational medicinal product has been manufactured in accordance with GMP guidelines.

Clinical trials data will be transferred to a centralized EU-database called "Eudract"

The new law has specific implications for the protection of clinical trial subjects. However, it will only be possible to evaluate the real impact of this reform once the applicable decrees have been implemented.


In light of the increasing deficit of the French Health Insurance System (E9.7 billion for 2002 and E11.6 billion for 2003) and in order to curb escalating costs and reduce the cost of supplying medicinal products, the French Government has decided to carry out a wide-ranging reform of the French Health Insurance System and to change existing provisions governing generics and the pharmaceutical reimbursement policy.

Further to the new law n° 2004-810 reforming the current system which was adopted on 13 August 2004, at the beginning of September of this year, the French Health Minister also announced that the main focus of French legislation would now be to expand the market for generics.

Generics substitution policy

(a) Extension of the definition of generic medicinal products

The law, adopted on 13 August 2004, implements Directive 2004/27/CE dated 31 March 2004 which modifies Article 10 of Directive 2001/83/CE regarding the new extended definition of generic medicinal products. It should be recalled that the term "generic medicinal product" refers to a medicinal product which has the same qualitative and quantitative composition as regards active substances and the same pharmaceutical form as the reference medicinal product. Article L. 5121-1 of the French Health Code now provides that the various salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance shall be considered to be the same active substance unless their properties differ significantly in terms of safety and/or efficacy. The implementation of the new definition aims to limit in particular the laboratories' practices of commercialising chemical derivatives from their active existing substances in order to keep their market shares for off-patents products.

(b) Promotion of the use of generics

Through the following measures, the French Health Minister has decided to significantly promote the use of generic products with the aim of achieving a use rate of nearly 30% by 2007, thus saving over one billion euros per year until 2007:

  1. A progressive reduction from 15 to 10 years being the time period for a drug to become a generic.
  2. A decree amending data protection for off-patent products is still being examined but should be adopted soon. This decree aims at implementing Directive 2004/27/CE of 31 March 2004 on medicinal products and therefore extending the protection not only to the products themselves, but to all of their various forms and dosages.

  3. A 10% reduction in the price of existing generics.
  4. Lower prices for newly-launched generics, that is, between 40% and 50% less than the brand-name drug as opposed to 28% at the moment.
  5. Extension of the application range for the reference price groups (the TFRs - "Tarifs forfaitaires de responsabilité") which permits off-patent products to be reimbursed at the price of generics. In the event that the generics substitution rates does not reach 60% in the first year and between 70% and 80% after two years, the TFR will be applied to the corresponding off-patent products.

Medicinal products reimbursement policy

The French Health Minister wants to save more than 2.5 billion euros per year until 2007 through the pharmaceutical reimbursement policy which is to be set up.

The new law has incorporated a new Health Authority, the "Haute Autorité en santé", which is entitled to evaluate and revaluate the level of reimbursement of medicinal products depending on their therapeutic efficiency (the "SMR" - "Service Médical rendu"). The Health French Minister will base his decision to reimburse or de-reimburse such medicinal products on the opinion of the new Health Authority.

Only pharmaceutical products with accurate packaging as defined in the applicable decree to be adopted will be registered on the list of medicinal products to be reimbursed.

A few other measures concerning the pharmaceutical industry include:

  1. Increase in the tax promotion on drugs and medical devices.
  2. Increase to 0.6% in the contribution rate for pharmaceutical companies which commercialise reimbursed medicinal products.


A new bioethics law n° 2004-800 was adopted on 6 August 2004 and has revised the preceding bioethics laws which were promulgated on 29 July 1994. This law has brought about numerous amendments, the main changes in the following areas:

Therapeutics cloning

Further to the general prohibition on reproductive cloning, the new law also prohibits the cloning of human embryos for therapeutic purposes. This criminal offence will be punished by a 100,000 euros fine and a seven year prison sentence.

Research on embryos

The law is reiterated in the French Health Code as regards (1) the prohibition on conceiving embryos by cloning, and (2) the prohibition on carrying out research on embryos. However, subject to the following conditions, a couple may authorise the carrying out of research on supernumerary frozen embryos during a period of five years:

  1. the research must not damage the embryo;
  2. the embryo must be supernumerary and no longer part of a parental project;
  3. if such research is likely to result in significant therapeutics benefits;
  4. if such research cannot be carried out with equivalent efficiency by using an alternative procedure; and
  5. if such research has been authorised by the competent Authority, the "Agence de biomédicine", which is established by the new law.

Such practices are also to be subject to an applicable decree which should be implemented shortly.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions